Table 2.

Baseline, follow-up, and change levels of B-vitamin markers in the B-PROOF DXA-sample

	Placebo					Intervention					p for difference in change
	n a	Baselineb	Follow-upb	Changec	p for change	n a	Baselineb	Follow-upb	Changec	p for change
Hcy (µmol/L)	561	14.3 [12.9–16.3]	14.4 [12.7–16.9]	0.2 (3.8)	0.522	545	14.3 [12.9–16.0]	10.5 [9.2–12.0]	−4.2 (3.0)	<0.001	<0.001
Folate (nmol/L)	553	19.1 [14.8–25.3]	24.6 [20.0–31.4]	6.5 (9.9)	<0.001	541	19.8 [15.4–24.8]	51.7 [41.2–64.2]	33.3 (24.3)	<0.001	<0.001
Vitamin B12 (pmol/L)	553	268 [104–343]	289 [226–392]	70 (585)	<0.001	541	272 [218–348]	592 [461–736]	327 (186)	<0.001	<0.001
MMA (µmol/L)	551	0.21 [0.17–0.29]	0.23 [0.18–0.30]	0.02 (0.15)	<0.001	540	0.21 [0.17–0.28]	0.18 [0.15–0.22]	−0.07 (0.17)	<0.001	<0.001
HoloTC (pmol/L)	557	65 [47–88]	62 [44–82]	−4 (34)	<0.001	545	70 [50–91]	126 [95–180]	63 (54)	<0.001	<0.001

MMA methylmalonic acid, HoloTC holotranscobalamin

^aParticipants from the DXA-sample with both a baseline and follow-up determination of a marker were included

^bPresented as median [interquartile range]

^cPresented as mean (standard deviation)